The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
News|Articles|March 10, 2020
INTERPHEX Rescheduled Due to COVID-19
Author(s)Pharmaceutical Technology Editors
New dates for the postponed event are still being determined.
Advertisement
Reed Exhibitions announced on March 11, 2020 that it was rescheduling its pharmaceutical industry event, INTERPHEX- originally scheduled to take place April 28–30 at the Javits Center in New York City-to July 15–17 at the same location because of concerns surrounding COVID-19.
“We know how important INTERPHEX is to our customers’ business and it is our top priority to provide the forum for INTERPHEX and Chemspec USA to allow business to continue,” said Randy Field, group vice president, Reed Exhibitions, in the press release. “The INTERPHEX community is uniquely equipped to support authorities and have a positive impact on addressing the COVID-19 virus. Therefore, we’ve made the decision to postpone INTERPHEX 2020 to July 15–17, 2020. We believe this is the right decision for our customers and the industry in general, which is a vital part of getting the pharmaceutical supply chain back on track post-outbreak.”
“We are working with our partners to find solutions to logistical and operational issues that may arise," Field added. "We are here to help, but ask for your patience as we ensure all of our customers are taken care of. With that in mind, please make sure to change hotels, flights, and any other arrangements. Information regarding airline change fee waivers is available on our website.”
Source:
Advertisement
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Shadow AI and vendor data retention put GMP records and trade secrets at risk. AI Pulse Check panelists outline what pharma AI policies require.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Advertisement
Advertisement